Sirini et al., 2023 - Google Patents
N-glycosylation inhibition hinders immunosuppressive tumor microenvironment cells improving CAR T cell efficacySirini et al., 2023
View PDF- Document ID
- 16488975379888080660
- Author
- Sirini C
- et al.
- Publication year
External Links
Snippet
La terapia CAR-T ha dimostrato impressionanti risultati verso tumori delle cellule B, ma ancora una ridotta efficacia contro i tumori solidi. In questo contesto, diversi ostacoli devono essere superati, tra cui un ridotto riconoscimento del tumore e la presenza di un …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Peng et al. | CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors | |
| Hadiloo et al. | The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors | |
| KR102659468B1 (en) | Compositions and methods for cancer immunotherapy | |
| US20220265709A1 (en) | Engineered cells and uses thereof | |
| CN112584844A (en) | Genome-edited constant natural killer T (INKT) cells for the treatment of hematologic malignancies | |
| TW202042824A (en) | Tn-muc1 chimeric antigen receptor (car) t cell therapy | |
| JP7436056B2 (en) | Medicaments, combinations, pharmaceutical compositions, immunoresponsive cells, nucleic acid delivery vehicles, and products for treating cancer | |
| Ai et al. | Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies | |
| US20250114386A1 (en) | Combination of a glycosylation inhibitor with one car cell therapy for treating cancer | |
| Wang et al. | Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells | |
| CN119998322A (en) | Gene editing targets genes to enhance natural killer cell function | |
| Guijarro-Albaladejo et al. | Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations | |
| Gao et al. | Recent advances in CAR‐T cell therapy for acute myeloid leukaemia | |
| Lutskovich et al. | State of the art and perspectives of chimeric antigen receptor T cells cell therapy for neuroblastoma | |
| US20240108651A1 (en) | Desmoglein 2-directed chimeric antigen receptor (CAR) constructs and methods of use | |
| Nasiri et al. | Updates on CAR T cell therapy in multiple myeloma | |
| US20250170182A1 (en) | Epitope engineering of cell-surface receptors | |
| Sirini | N-glycosylation inhibition hinders immunosuppressive tumor microenvironment cells improving CAR T cell efficacy | |
| Paubelle et al. | Chimeric antigen receptor-engineered T cell therapy in acute myeloid leukaemia | |
| TW202511490A (en) | Armored t cells | |
| Azeez et al. | Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives | |
| HK40074698A (en) | Drug for treating cancer, combination drug, drug composition, immune responsive cell, nucleic acid delivery vehicle, and product | |
| O'Brien‐Gore et al. | Cancer immunotherapy | |
| Han et al. | Designs of NKG2D-based immunotherapeutics for cancer | |
| WO2023235479A1 (en) | Compositions and methods for treating cancer |